{
    "paper_id": "b32f36f5c880d8ddb7b526b91088a4dd2b4b1252",
    "metadata": {
        "title": "Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19",
        "authors": [
            {
                "first": "Bo",
                "middle": [],
                "last": "Yu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Chenze",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Peng",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ning",
                "middle": [],
                "last": "Zhou",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Luyun",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Jia",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {
                    "laboratory": "State Key Laboratory of Drug Research",
                    "institution": "Chinese Academy of Sciences",
                    "location": {
                        "addrLine": "555 Zu Chong Zhi Road",
                        "postCode": "201203",
                        "settlement": "Shanghai",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Hualiang",
                "middle": [],
                "last": "Jiang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Wen",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Wen",
                "middle": [],
                "last": "Dao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Huazhong University of Science and Technology",
                    "location": {
                        "postCode": "430030",
                        "settlement": "Wuhan",
                        "country": "China"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Since the breakout of infection by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 in Wuhan, China 1 More recently, plasma of convalescent patients was used in Wuhan to manage refractory patients successfully but the scope of this treatment is greatly constrained due to the limited supply of effective plasma.",
            "cite_spans": [
                {
                    "start": 139,
                    "end": 140,
                    "text": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Chloroquine and hydroxychloroquine are two classic drugs 5 , which were originally used to treat malaria. In recent years, repurpose of existing drugs such as chloroquine class of drugs for other diseases has received increasingly growing attention 5, 6 . Chloroquine and hydroxychloroquine have been used to treat rheumatological and immunological diseases because their All rights reserved. No reuse allowed without permission.",
            "cite_spans": [
                {
                    "start": 249,
                    "end": 251,
                    "text": "5,",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 252,
                    "end": 253,
                    "text": "6",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The key to reduce mortality of COVID-19, however, is to cure critically ill patients. This study demonstrates that hydroxychloroquine application, a less toxic derivative of chloroquine, is significantly associated with a decreased mortality in critically ill patients with COVID-19 by attenuating the inflammatory cytokine storm.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "This investigation is a retrospective study involving critically ill patients with ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design"
        },
        {
            "text": "All patients have medical history and imaging characteristics of COVID-19 and have been confirmed with SARS-CoV-2 infection by laboratory tests. In All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patients' information"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patients' information"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint addition, all patients were confirmed by chest computed tomography (CT) and SARS-CoV-2 pathogenic test. The inclusion for critically ill patients has to meet one of the following criteria: 1) patients had respiratory failure and needed mechanical ventilation; 2) patients had septic shock during hospitalization; 3) patients with other organ failures that required monitoring and treatment by intensive care unit. In this study, we included all critically ill patients with hospitalization during the epidemic period from February 1 of 2020 to April 8 of 2020.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patients' information"
        },
        {
            "text": "Health care data of COVID-19 patients, including medical history, chest CT, and laboratory tests, in-hospital therapies, and clinical deposits (death or cured discharge), were extracted by data coordinators through the electronic medical records. Laboratory test results included inflammatory cytokines and counts of white blood cells in peripheral blood.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data collection of patients"
        },
        {
            "text": "Continuous values were expressed as medians and interquartile range (Q1-Q3) and categorical variables as counts and percentages. The comparisons of continuous values between groups were performed with Wilcoxon rank-sum tests. For paired continuous variables, paired sample Wilcoxon rank test was used. Categorical variables were compared using Chi-square test. Survival curves was described by Kaplan-Meier method and compared with the log-rank test. Cox regression were performed to determine hazard ratios (HRs) and 95% confidence intervals (CIs). In the mulitivariable model, we adjusted for age, sex, history of hypertension, diabetes mellitus, coronary heart disease, and COPD, and oxygen saturation, as well as baseline treatment drugs. All comparisons were two-tailed, and p < 0.05 was considered as statistically significant. All statistical analyses were performed with R packages (version 3.1.4, Vienna, Austria). All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical analysis"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical analysis"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical analysis"
        },
        {
            "text": "From February 1 of 2020, through April 8 of 2020, a total 568 critically ill COVID-19 patients were admitted to Tongji Hospital, 358 males and 210 females. Median ages were 68 years old; 48 patients received hydroxychloroquine treatments (HCQ) (oral 200 mg twice per day for 7-10 days) and remaining 520 receiving basic treatments (non-hydroxychloroquine treatments, NHQC). Between these two groups, baseline characteristics including age, genders, original comorbidities, as well as severity of disease were not different (table 1) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 523,
                    "end": 532,
                    "text": "(table 1)",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Study patients"
        },
        {
            "text": "In total of 568 patients, 247 patients died (mortality was 43.5%). In order to eliminate the influence of confounding factors, we performed Cox All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study outcomes"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study outcomes"
        },
        {
            "text": "Laboratory tests showed that in HCQ group, IL-6 level in plasma was 5.2 (Figure 2 ). Furthermore, we analyzed the change of IL-6 level during the hospitalization period and found that IL-6 level was lowered after HCQ application and kept the lower level stable during therapy period. However, interestingly, after hydroxychloroquine treatment stopped, inflammatory mediator IL-6 level went up to control level ( Figure 3 ). All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 72,
                    "end": 81,
                    "text": "(Figure 2",
                    "ref_id": "FIGREF7"
                },
                {
                    "start": 412,
                    "end": 420,
                    "text": "Figure 3",
                    "ref_id": "FIGREF8"
                }
            ],
            "section": "Effect of hydroxychloroquine on inflammatory cytokines"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Effect of hydroxychloroquine on inflammatory cytokines"
        },
        {
            "text": "This retrospective study found that hydroxychloroquine application is significantly associated with a decreased mortality in critically ill patients with COVID-19 and lower level of IL-6, one of most inflammatory cytokines. We also found that the length of hospital stay in the hydroxychloroquine-treated non-survivors is longer than in non-hydroxychloroquine-treated non-survivors, suggesting that hydroxychloroquine could prolong the lifetime of critically ill patients even if their lives were eventually lost, which further supports that hydroxychloroquine has therapeutic effects for critically ill patients of COVID-19. Importantly, we found that the role that hydroxychloroquine application associated with a decreased plasma IL-6 level is highly consistent with the duration of its administration, and once the drug stops, plasma IL-6 level rises up to control level.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "We have noted that hydroxychloroquine has in vitro antiviral effects on several viruses, including SARS, and SARS-CoV-2 7-10 , which may contribute directly to its therapeutic effect to COVID-19 patients. However, the anti-SARS-CoV2 action of chloroquine does not seems to account for the significant efficiency to critically ill patients in our cohort.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "COVID-19 patients displayed obvious immunity disorders, showing marked reduction in lymphocyte numbers in peripheral blood and lymphatic tissues, but huge amount of lymphocyte infiltration in lungs as well as in other critical organs such as heart. Many patients showed symptoms of cytokine storm with markedly-elevated levels of the proinflammatory cytokine IL-6, suggesting overactivated immune responses 11 . Anti-IL-6 antibody, Tocilizumab, has been been shown to be an effective treatment option for COVID-19 patients with a risk of cytokine storms. 12 In this study, we demonstrate that hydroxychloroquine can mimic the effect of anti-IL-6 antibody by observing decreased levels of Il-6 in the critically ill COVID-19 patients after All rights reserved. No reuse allowed without permission.",
            "cite_spans": [
                {
                    "start": 407,
                    "end": 409,
                    "text": "11",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 555,
                    "end": 557,
                    "text": "12",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 13, 14 , and inhibit proinflammatory cytokines through inhibition of lysosomal-autophagy pathways 14 Additionally, a decreased plasma IL-6 level after hydroxychloroquine use is highly consistent with its application period and after stopped its role disappear and IL-6 level increases to the level of non-hydroxychloroquine patients. This finding indicates that we need to adjust our treatment regimen, that is, to keep use hydroxychloroquine until patients are completely cured.",
            "cite_spans": [
                {
                    "start": 129,
                    "end": 132,
                    "text": "13,",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 133,
                    "end": 135,
                    "text": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 227,
                    "end": 229,
                    "text": "14",
                    "ref_id": "BIBREF13"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "In summary, this retrospective study demonstrates that hydroxychloroquine application is associated with a decreased risk of death in critically ill COVID-19 patients without obvious toxicity and its mechanisms of action is probably mediated through its inhibition of inflammatory cytokine storm on top of its ability in inhibiting viral replication. Therefore, hydroxychloroquine should be considered as a primary option to apply to treat critically ill COVID-19 patients, which could save lives during the current COVID-19 pandemic despite that randomized-double blind control study is needed to provide All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint stronger evidence. Although this retrospective study was performed with the critically ill COVID-19 patients, hydroxychloroquine should also be an option for early stage of patients because the safety records and their long history of use in treating malaria infections. All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . The percentage represented the frequency divided by the total cohort size (n=568).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "Mechanical ventilation contained Non-invasive ventilation and Invasive ventilation Data were presented as medians and interquartile range (Q1-Q3). HCQ, Hydroxychloroquine treatment; NHCQ, non-Hydroxychloroquine treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. Data were presented as medians and interquartile range (Q1-Q3). HCQ, hydroxychloroquine treatment; NHCQ, non-hydroxychloroquine treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "Y"
                    ],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Chinese management guideline for COVID-19 (version 5.0)",
            "authors": [
                {
                    "first": "China",
                    "middle": [],
                    "last": "Nhco",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Compassionate Use of Remdesivir for Patients with Severe Covid-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Grein",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ohmagari",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Shin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2007016"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "Q"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105954"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "D"
                    ],
                    "last": "Rainsford",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Parke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Clifford-Rashotte",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "F"
                    ],
                    "last": "Kean",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Inflammopharmacology",
            "volume": "23",
            "issn": "5",
            "pages": "231--269",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Plantone",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Koudriavtseva",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Drug Investig",
            "volume": "38",
            "issn": "8",
            "pages": "653--671",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Discov",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "J-C",
                    "middle": [],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases",
            "authors": [
                {
                    "first": "Al-Bari",
                    "middle": [],
                    "last": "Maa",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Antimicrob Chemother",
            "volume": "70",
            "issn": "6",
            "pages": "1608--1621",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yao",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Clin Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/cid/ciaa237"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.21203/rs.3.rs-19346/v1"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Tocilizumab treatment in COVID-19: a single center experience",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Medl Virol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25801"
                ]
            }
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "An in vitro test system for compounds that modulate human inflammatory macrophage polarization",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shiratori",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Feinweber",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Luckhardt",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Europ J Pharmacol. Aug",
            "volume": "15",
            "issn": "",
            "pages": "328--338",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "COVID-19, cytokines and immunosuppression",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Sarzi-Puttini",
                    "suffix": ""
                },
                {
                    "first": "Giorgi",
                    "middle": [
                        "V"
                    ],
                    "last": "Sirotti",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "this awful epidemic and help frontline physicians to treat patients and save lives, the World Health Organization (WHO), China, and many other countries have issued preliminary guidance on screening and diagnosis of infections in populations as well as managements of infection control. However, because of the lack of effective remedy for COVID-19, the recommended treatment for acutely ill patients are severely limited, with options for compassionate managements that include the use of Chinese herbs 2 . Although these strategies help many patients, especially in China, severe and especially critically ill patients are with high risk of death. Recent clinical trials on antiviral drugs such as Arbidol have not shown significant therapeutic benefit and the effect of Remdesivir still needs more evidence 3 . Recently clinical observation suggest that Tocilizumab against interleukin 6 (IL-6), a major proinflammatory cytokine, to calm down the cytokine storm caused by SARS-CoV-2 infection, could lead to therapeutic effects in portion of patients 4 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "COVID-19 in Tongji Hospital, Wuhan, China. These patients were diagnosed according to the WHO interim guideline and the Clinical Guideline for COVID-19 Diagnosis and Treatment published by the National Health Commission of China between February 1 of 2020 and April 8 of 2020. This study has been approved by the institutional review board of Tongji Hospital (IRBID: TJ-C20200113). The written informed consent has been waived by the Ethics Committee because of the retrospective and anonymous nature of the data.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "23.4) pg/mL after HCQ application, which significant lower than the IL-6 level before HCQ application (22.2 [8.3-118.9] pg/mL, p=0.002), but there is little change in NHCQ patients (21.3 [8.8-62.8] pg/mL vs. 20.2 [6.1-94.4] pg/mL, p 0.05]",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "and formation of double membrane vesicles 6,15 , a process required for genome replication by the SARS Coronavirus Replication Complex 16 . Thus, its anti-inflammatory action of hydroxychloroquine in combination of its inhibitory of viral replication may contribute greatly to its therapeutic effects on critically ill COVID-19 patients. In addition, tissue distribution of hydroxychloroquine is unique and favors therapy of pneumonia because it has much higher concentrations in lungs 17 . Importantly, the chloroquine class of drugs have been showed to repress inflammation with great synergy with low concentrations of glucocorticoids, one of the most potent classes of anti-inflammatory drugs, pointing to possibility of combined therapy of hydroxychloroquine with low dose of glucocorticoids 14 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Nos. 31130031), Emergency project fund of Chinese Academy of Sciences (No. 2020YJFK0105) and Chinese Academy of Engineering and Ma Yun Foundation (No. 2020-CMKYGG-05). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author announcements: 1. Conflicts of interest: The authors have declared that no competing interests exist. 2. Its content, figures, and tables have not been published or submitted elsewhere in print or electronic format and will not be submitted elsewhere during the period of review by SCIENCE CHINA Life Sciences. 16. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. Jun 2006;80(12):5927-5940.17.McChesney EW, Banks WF, Fabian RJ. Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol App Pharmacol.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Figure legends",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Kaplan",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Effects of hydroxychloroquine treatment on plasma level of IL-6. Hydroxychloroquine treatment is associated with a decreased level of IL-6 in about 5 (4-8) days, *P<0.05 (A). The level of IL-6 did not change in non-hydroxychloroquine treatment group at the same observation time (B).HCQ, hydroxychloroquine; NHCQ, non-hydroxychloroquine.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Continuous curve of plasma levels of IL-6 showing that the consistency of hydroxychloroquine treatment period with lowering IL-6 level. All rights reserved. No reuse allowed without permission.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "inhibition of immunity and proinflammatory cytokines. Chloroquine and hydroxychloroquine also have antimicrobial effects and were used to treat infections by bacteria and virus. Recently, Liu et al. suggested that hydroxychloroquine is effective in inhibiting SARS-CoV-2 infection cell-based assays 7 and Gautret et al demonstrated hydroxychloroquine treatment is significantly associated with reduction and disappearance of viral load in COVID-19 patients in a small size sample 8 , which instigated new hope for an effective treatment for COVID-19.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Nine out of 48 HCQ patients (18.8%) died, while in NHCQ group, 238/520 (45.8%) patients died (p<0.001). Furthermore, average hospital stay time are 32 (26-41) days in HCQ group and 30 (18-40) days in NHCQ-treated patients (p=0.098), but hospital stay time before death from admission was longer in HCQ patients than NHCQ subjects [15 (10-21) vs. 8 (4-14)] days (p=0.021) (Table 2, and Figure 1A). The baseline treatments were comparable for these two groups, including application of antiviral drugs (Lopinavir and Ritonavir, Entecavir hydrate, or Ribavirin) with 41.7% and 44.4% patients in HCQ and NHCQ, respectively, (p=0.71); intravenous immunoglobulin in 52.1% in HCQ and 47.1% patients in NHCQ, respectively (p=0.51); immunoenhancer in 16.7% in HCQ and 17.3% patients in NHCQ, respectively (p=0.91), but antibiotics in 77.1% in HCQ and 89.4% patients in NHCQ, respectively (p=0.01); but interferon application 0% in HCQ and 10.4% patients in NCHQ (p=0.01).",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint regression analysis for age, sex, history of hypertension, diabetes mellitus, coronary heart disease, and COPD, and oxygen saturation, and results showed that the use of hydroxychloroquine was associated with a significantly",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "hydroxychloroquine application. In addition, hydroxychloroquine can modulate human inflammatory macrophage polarization via downregulating M1 but upregulating M2 macrophages",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Baseline characteristics of critically ill COVID-19 patientsAbbreviations: HCQ, hydroxychloroquine; COPD, chronic obstructive pulmonary disease; SpO 2 , percutaneous oxygen saturation.",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": ". https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "Comparison of clinical outcomes between HCQ treated and non HCQ treated patients.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "We thank all our colleagues from the Department of Internal Medicine, Tongji Hospital, as well as all the medical staffs fighting against COVID-19, for their tremendous efforts. We also thank Professor H. Eric Xu in Shanghai Institute of Materia Medica, Chinese Academy of Sciences for his great help in writing this paper.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acknowledgments"
        }
    ]
}